Doer Biologics begins patient dosing in phase 2 study of DR10624 to treat metabolic dysfunction-associated steatotic liver disease and MASH: Hangzhou, China Thursday, April 24, 20 ...

The future of treating metabolic dysfunction–associated steatohepatitis (MASH) looks brighter than ever, says Naim Alkhouri, MD, as data emerges on newly developed interventions.

In one study, once-daily danuglipron resulted in one patient who experienced drug-related elevated liver enzymes.

The frequency of high blood glucose among patients receiving PI3K/Akt inhibitors to treat breast cancer has some oncologists ...

Pfizer has terminated the development of its oral obesity candidate danuglipron after a patient on a clinical trial with the ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of science, technology, and medicine news ...

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data from its Phase 2a clinical ...

A new expert review endorses GLP-1 RAs and other medications for sustainable weight loss in children with obesity and MASLD.

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

Pfizer has ended development of danuglipron, an oral GLP-1 drug for weight management, citing clinical data and regulatory input.

Pfizer has announced the decision to discontinue the development of danuglipron, an oral glucagon-like peptide-1 (GLP-1) ...